Total medical devices industry venture financing deals in June 2020 worth $1.01bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 38.4% over the previous month and a drop of 8.7% when compared with the last 12-month average, which stood at $1.1bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $645.56m. At the country level, the US topped the list in terms of deal value at $645.48m.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of venture financing deals activity in June 2020 was the US with 41 deals, followed by China with 12 and the UK with seven.
In 2020, as of the end of June 2020, medical devices venture financing deals worth $7.81bn were announced globally, marking an increase of 47.1% year on year.
Medical devices industry venture financing deals in June 2020: Top deals
The top five medical devices industry venture financing deals accounted for 31.4% of the overall value during June 2020.
The combined value of the top five medical devices venture financing deals stood at $315.37m, against the overall value of $1.01bn recorded for the month.
The top five medical devices industry deals of June 2020 tracked by GlobalData were:
1) ACME Capital, Decheng Capital, Foresite Capital Management, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners’ $100m venture financing of Cue Health
2) The $64m venture financing of Somatus by Blue Venture Fund, Deerfield ManagementLP, Flare Capital Partners, Longitude Capital Management Co, Optum Ventures and Town Hall Ventures
3) Abbott Laboratories, Cormorant Asset Management, Janus Henderson Investors, Quadrant Capital Advisors, Senvest Capital and Smile Group’s $55m venture financing of Bigfoot Biomedical
4) The $51.97m venture financing of Spineart Geneva by EGS Beteiligungen
5) Viking Global Investors’ venture financing of Infinity BiologiX for $44.4m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.